Vitamin D and vitamin D analogs in cancer treatment

Curr Drug Targets. 2002 Feb;3(1):85-94. doi: 10.2174/1389450023348064.

Abstract

The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is a key player in the regulation of bone mineralization and calcium homeostasis. In addition, 1,25-(OH)2D3 has antiproliferative and prodifferentiation effects on various cells in vitro and in vivo. The growth-inhibitory properties of 1,25-(OH)2D3 could be harnessed in the treatment of cancer. However, its use as an anti-cancer drug is limited because of the calcemic effects of pharmacological doses. In an attempt to dissociate the antiproliferative and calcemic effects, numerous vitamin D3 analogs were developed. The mechanisms by which 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs exert their growth-inhibitory effects are not clear but include effects on cell differentiation, apoptosis, cell cycle regulation, metastases, and angiogenesis. In the current review aspects involved in the tumor suppressive activity of 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs will be addressed. The use of vitamin D3 compounds, alone or in combination with other drugs, in cancer treatment and the potential drawbacks will also be discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Death / drug effects
  • Cell Death / physiology
  • Cell Differentiation / drug effects
  • Cell Differentiation / physiology
  • Clinical Trials as Topic / statistics & numerical data
  • Humans
  • Neoplasms / drug therapy*
  • Vitamin D / analogs & derivatives*
  • Vitamin D / pharmacology
  • Vitamin D / therapeutic use*

Substances

  • Vitamin D